Wu Qiuwen, Fu Jiaxin, Zhu Bin, Meng Wei, Ma Jingyi, Lv Ying, Zhao Wenqi, Wang Fan, Liu Jingjin, Wang Yongshun, Peng Cong, Zhang Shuo
Department of Cardiology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
National Key Laboratory of Frigid Zone Cardiovascular Diseases (NKLFZCD), The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, 150001, China.
Cell Commun Signal. 2025 Jan 28;23(1):52. doi: 10.1186/s12964-025-02045-x.
Oxidative stress-associated proximal tubular cells (PTCs) damage is an important pathogenesis of hypertensive renal injury. We previously reported the protective effect of VEGFR3 in salt-sensitive hypertension. However, the specific mechanism underlying the role of VEGFR3 in kidney during the overactivation of the renin-angiotensin-aldosterone system remains unclear. In the present study, hypertensive nephropathy was established by angiotensin II (Ang II). We found that VEGFR3 was highly increased in PTCs of Ang II-infused mice. Activation of VEGFR3 mitigated renal dysfunction, pathological damage, and oxidative stress in Ang II-induced hypertensive mice. Moreover, we found that VEGFR3 restored mitophagy deficiency induced by Ang II both in vivo and in vitro to alleviate oxidative stress injury in PTCs. Furthermore, in vitro experiment demonstrated that VEGFR3 improved abnormal mitophagy by enhancing PARKIN mitochondrial translocation. LC-MS/MS and Co-IP assays identified HSPA1L as the interacted protein of VEGFR3, which promoted the mitochondrial translocation of PARKIN. Mechanistically, VEGFR3 disorder domain bound to HSPA1L, and crotonylation modification of HSPA1L at K130 by VEGFR3 was required for mitophagy regulation in the context of Ang II-induced PTCs. Finally, the protective effect of VEGFR3 on mitophagy and oxidative stress were attenuated by transfection K130 (HSPA1L-K130R) mutant plasmid in vivo and in vitro. These findings indicated that VEGFR3 alleviated oxidative stress by promoting PARKIN-dependent mitophagy pathway via regulating HSPA1L crotonylation at K130 site in Ang II-induced PTCs, which provided a mechanistic basis for the therapeutic target in hypertensive renal injury.
氧化应激相关的近端肾小管细胞(PTCs)损伤是高血压肾损伤的重要发病机制。我们之前报道了VEGFR3在盐敏感性高血压中的保护作用。然而,在肾素 - 血管紧张素 - 醛固酮系统过度激活期间,VEGFR3在肾脏中作用的具体机制仍不清楚。在本研究中,通过血管紧张素II(Ang II)建立高血压肾病模型。我们发现,在注射Ang II的小鼠的PTCs中VEGFR3高度增加。VEGFR3的激活减轻了Ang II诱导的高血压小鼠的肾功能障碍、病理损伤和氧化应激。此外,我们发现VEGFR3在体内和体外均可恢复由Ang II诱导的线粒体自噬缺陷,以减轻PTCs中的氧化应激损伤。此外,体外实验表明,VEGFR3通过增强PARKIN向线粒体的转位改善异常的线粒体自噬。LC-MS/MS和Co-IP分析确定HSPA1L为VEGFR3的相互作用蛋白,其促进PARKIN向线粒体的转位。机制上,VEGFR3的无序结构域与HSPA1L结合,在Ang II诱导的PTCs环境中,VEGFR3对HSPA1L第130位赖氨酸的巴豆酰化修饰是线粒体自噬调节所必需的。最后,在体内和体外转染K130(HSPA1L-K130R)突变体质粒可减弱VEGFR3对线粒体自噬和氧化应激的保护作用。这些发现表明,在Ang II诱导的PTCs中,VEGFR3通过调节HSPA1L第130位赖氨酸位点的巴豆酰化,促进依赖PARKIN的线粒体自噬途径,减轻氧化应激,这为高血压肾损伤的治疗靶点提供了机制基础。